the Hypertrophic Scar Prevention of BMT101.

• Status: Recruiting
• Trial end date: 2022-08-31
• Target enrollment: 0
• Participant gender: All

Summary

An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hugel

Criteria

Inclusion Criteria:

• male and female adults aged 19-55 years

• Those who plan to undergo a revision surgery to remove hypertrophic scar resulted from a previous abdominal surgery

• Those who voluntarily signed the written consent and agreed to participate in the study.

Exclusion Criteria:

• Pregnant or lactating women

• Those with clinically significant systemic disease (e.g. diabetes, hematologic disease, allergic or immunogenic systemic skin disease)